The review received financial support from Avadel Pharmaceuticals, which recently filed a new drug application  with the US Food & Drug Administration (FDA) for a once-nightly formulation of sodium oxybate. Sodium oxybate is currently available with twice-nightly dosing from Jazz Pharmaceuticals under the brand name Xyrem. Jazz recently received FDA approval for narcolepsy drug Xywav (calcium, magnesium, potassium, and sodium oxybates), which has 92% less sodium content than Xyrem.